VFA
KROS icon

Virtus Fund Advisers’s Keros Therapeutics KROS Stock Holding History

Virtus Fund Advisers’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-535
Closed -$21.5K – 109
2023
Q2 		$21.5K Hold
535
– – 0.15% 93
2023
Q1 		$22.8K Hold
535
– – 0.16% 93
2022
Q4 		$25.7K Buy
+535
New +$25K 0.18% 88

Other funds holding KROS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Virtus Fund Advisers's KROS Position: Q3 2023 in Review

Virtus Fund Advisers sold out of Keros Therapeutics (KROS) in Q3 2023, closing a stake of 535 shares — an estimated $21.5K sold.

Virtus Fund Advisers first reported a position in KROS in Q4 2022 and held it in 3 quarters. The position peaked at $25.7K in Q4 2022. 107 funds tracked by Wall St. Rank hold KROS as of Q3 2023.

  • Virtus Fund Advisers reported no remaining Keros Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Virtus Fund Advisers sold 535 Keros Therapeutics shares in Q3 2023, an estimated $21.5K.
  • Virtus Fund Advisers first reported a position in Keros Therapeutics in Q4 2022 and held it in 3 quarters.
  • Virtus Fund Advisers's Keros Therapeutics position peaked at $25.7K in Q4 2022.
  • 107 funds tracked by Wall St. Rank held Keros Therapeutics as of Q3 2023.

Based on Virtus Fund Advisers's 13F filing for Q3 2023, filed 8 Nov 2023.